Skip to content

Newsroom

type
year
reltype
Illustration image.png

Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics

1/30/2025 Press release
Illustration image.png

Orion publishes Financial Statement Release for 2024 and holds a webcast on 25 February 2025

1/28/2025 Press release
Illustration image.png

Inside information: Orion upgrades full-year outlook for 2024 and provides preliminary information on financial performance for 2024

1/15/2025 Stock exchange release
Illustration image.png

Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2025 Annual General Meeting

1/15/2025 Stock exchange release
Illustration image.png

79,345 Orion Corporation A shares converted into B shares

1/13/2025 Stock exchange release
Illustration image.png

Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide

1/7/2025 Press release
Illustration image.png

Orion and Marinus terminate agreement for ganaxolone in Europe

12/30/2024 Press release
Illustration image.png

CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

12/19/2024 Stock exchange release
Illustration image.png

Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

12/19/2024 Stock exchange release
Illustration image.png

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

12/18/2024 Press release
Illustration image.png

Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction

12/12/2024 Stock exchange release
Illustration image.png

142,701 Orion Corporation A shares converted into B shares

11/27/2024 Stock exchange release
Illustration image.png

Orion Research Foundation grants EUR 1,109,000 for research in 2025

11/22/2024 Press release
Illustration image.png

Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies

11/19/2024 Press release
Illustration image.png

Orion Corporation: Managers’ transactions – Henrik Stenqvist

11/1/2024 Managers transactions
Illustration image.png

Orion Group Interim Report January–September 2024

10/29/2024 Stock exchange release
Illustration image.png

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

10/24/2024 Stock exchange release
Illustration image.png

Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024

10/15/2024 Press release